Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials

被引:77
作者
Monami, Matteo [1 ]
Vitale, Valentina [2 ,3 ]
Ambrosio, Maria Luisa [1 ]
Bartoli, Nadia [1 ]
Toffanello, Giulia [1 ]
Ragghianti, Benedetta [2 ,3 ]
Monami, Francesca [1 ]
Marchionni, Niccolo [1 ]
Mannucci, Edoardo [2 ,3 ]
机构
[1] Azienda Osped Univ Careggi, Florence, Italy
[2] Careggi Teaching Hosp, Diabet Agcy, Florence, Italy
[3] Univ Florence, Florence, Italy
关键词
Acarbose; Dipeptidyl peptidase 4 inhibitor; Lipid profile; Pioglitazone; Sulfonylureas; Type; 2; diabetes; INITIAL COMBINATION THERAPY; TYPE-2; DIABETES-MELLITUS; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR RISK-FACTORS; ONGOING METFORMIN THERAPY; IMPROVES GLYCEMIC CONTROL; ORAL ANTIDIABETIC AGENTS; CORONARY-HEART-DISEASE; DOUBLE-BLIND; BLOOD-PRESSURE;
D O I
10.1007/s12325-012-0045-5
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Lipid profile is an important determinant of cardiovascular risk in type 2 diabetes. It is well known that patients with type 2 diabetes are more likely to be dyslipidemic than the general population. Given the observed connection between glucose and lipid metabolism in patients with type 2 diabetes, it is conceivable that different glucose-lowering agents can have a varying impact on the lipid profile. When metformin monotherapy fails, other drugs can be added to achieve sufficient glycemic control. Available oral agents include pioglitazone, acarbose, dipeptidyl peptidase 4 (DPP-4) inhibitors, and insulin secretagogs. The present meta-analysis was designed to assess the effect of DPP-4 inhibitors, pioglitazone, insulin secretagogs, and acarbose on blood lipids when compared to placebo. An extensive search (any date up to November 1, 2011) was performed for all trials performed on the following classes of drugs: gliptin, insulin secretagogs, pioglitazone, and acarbose. The following endpoints were considered: endpoint total, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) and triglycerides. The difference in mean total cholesterol values at endpoint versus baseline was significantly higher in patients on pioglitazone, sulfonylureas, and DPP-4 inhibitor treatment (but not on acarbose) than those on placebo, demonstrating that treatment with these drugs (except acarbose) is associated with a significant reduction in total cholesterol. With respect to triglycerides, a significant reduction could be observed with acarbose, pioglitazone, and DPP-4 inhibitors, but not with sulfonylureas. HDL-C appeared to be increased by treatment with acarbose and pioglitazone, and decreased by sulfonylureas. The present meta-analysis shows that available glucose-lowering drugs may have varying effects on the lipid profile. DPP-4 inhibitors, acarbose, and pioglitazone seem to have a more favorable effect on the lipid profile than sulfonylureas.
引用
收藏
页码:736 / 746
页数:11
相关论文
共 55 条
[1]  
[Anonymous], CARD OUTC STUD AL SU
[2]  
[Anonymous], CAROLINA CARD OUTC S
[3]  
[Anonymous], TECOS SIT CARD OUTC
[4]  
[Anonymous], STAND MED CAR DIAB 2
[5]  
[Anonymous], GUID GUID
[6]  
[Anonymous], SAVOR TIMI 53 DOES S
[7]  
[Anonymous], GUID
[8]   Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus [J].
Araki, Takahiro ;
Emoto, Masanori ;
Konishi, Toshiaki ;
Ikuno, Yoshiko ;
Lee, Eiko ;
Teramura, Megumi ;
Motoyama, Koka ;
Yokoyama, Hisayo ;
Mori, Katsuhito ;
Koyama, Hidenori ;
Shoji, Tetsuo ;
Nishizawa, Yoshiki .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2009, 58 (02) :143-148
[9]   Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study [J].
Aronoff, S ;
Rosenblatt, S ;
Braithwaite, S ;
Egan, JW ;
Mathisen, AL ;
Schneider, RL .
DIABETES CARE, 2000, 23 (11) :1605-1611
[10]   Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes [J].
Aschner, P. ;
Katzeff, H. L. ;
Guo, H. ;
Sunga, S. ;
Williams-Herman, D. ;
Kaufman, K. D. ;
Goldstein, B. J. .
DIABETES OBESITY & METABOLISM, 2010, 12 (03) :252-261